AnaptysBio (NASDAQ:ANAB) Posts Earnings Results, Beats Estimates By $5.57 EPS

AnaptysBio (NASDAQ:ANAB) issued its earnings results on Monday. The biotechnology company reported $5.11 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $5.57, FiscalAI reports. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. The firm had revenue of $27.49 million for the quarter, compared to analysts’ expectations of $14.06 million. During the same quarter last year, the company earned ($1.30) earnings per share.

AnaptysBio Trading Down 1.8%

NASDAQ:ANAB opened at $53.92 on Wednesday. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of 10.04 and a beta of 0.71. AnaptysBio has a twelve month low of $13.81 and a twelve month high of $72.36. The company has a 50-day moving average of $55.67 and a 200-day moving average of $59.22.

Analysts Set New Price Targets

ANAB has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of AnaptysBio in a research report on Tuesday. TD Cowen decreased their price objective on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 25th. Zacks Research lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of AnaptysBio in a research note on Friday, August 7th. Finally, HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of AnaptysBio in a research report on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and an average target price of $79.85.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.